

EQA round: VVV2/24 - Maternal Diagnostic Screening (Triple Test)

Deadline: 1.11.2024

Setup: groups - R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Set 1														
(238) free β-hCG	[U/L]				9							9	8	89
Sample A1		47,5	2,8	5,8	9							9	9	100
(60) Roche		46,3	4,5	9,7	8	0	CVPG	47,4	0,96	15%	40,2	54,6	8	
Other					1	0							1	
							1x 24							
Sample B1		55,6	1,6	2,8	9							9	8	89
(60) Roche		54,8	2,7	4,9	8	0	CVPG	55,6	0,78	15%	47,2	64	8	
Other					1	0							1	
							1x 24							
(239) PAPP-A	[U/L]				12							12	10	83
Sample A1		0,341	0,057	17	12							12	10	83
(60) Roche		0,342	0,062	18	10	0	CVPG	0,357	0,012	20%	0,285	0,429	10	
Other					2	0							2	
							2x 24							
Sample B1		1,18	0,13	11	12							12	12	100
(60) Roche		1,18	0,13	11	10	0	CVPG	1,2	0,039	20%	0,96	1,44	10	
Other					2	0							2	
							2x 24							
Set 2														
(370) AFP	[µg/L]				12							10	10	100
Sample A2		31,5	4,5	14	12							10	10	100
(60) Roche		33,7	1,3	4	6	0	CVPG	33,9	1,5	20%	27,1	40,7	6	
Other					6	0							4	
							1x 1, 4x 12, 1x 179							
Sample B2		19,7	2,7	14	12							10	10	100
(60) Roche		21,4	1,9	8,7	6	0	CVPG	21,5	0,91	20%	17,2	25,8	6	
Other					6	0							4	
							1x 1, 4x 12, 1x 179							
(373) hCG	[kU/L]				12							9	9	100
Sample A2		32,3	5,2	16	12							9	9	100
(60) Roche		28,9	1,7	6	6	0	CVPG	27,3	1,4	18%	22,3	32,3	6	
Other					6	0							3	
							1x 1, 3x 12, 1x 36, 1x 179							
Sample B2		61,3	10	16	12							9	9	100
(60) Roche		56,7	4	7	6	0	CVPG	53,3	2,7	18%	43,7	62,9	6	
Other					6	0							3	
							1x 1, 3x 12, 1x 36, 1x 179							
(375) Estriol unconjug.	[nmol/L]				12							12	9	75
Sample A2		2	1,4	72	12							12	11	92
(12) Beckman Coulter		3,38	0,24	7	5	0	CVPG	3,15	0,18	33%	2,11	4,19	5	
(29) Siemens (Immulite)		1,08	0,27	25	7	0	CVPG	1,12	0,22	33%	0,75	1,49	7	
Sample B2		0,99	0,75	76	12							12	9	75
(12) Beckman Coulter		1,72	0,13	7,3	5	0	CVPG	1,7	0,11	33%	1,13	2,27	5	
(29) Siemens (Immulite)		0,515	0,14	27	7	0	CVPG	0,453	0,12	33%	0,303	0,603	7	
1. trimester														
(240) free β-hCG (MoM)	[MoM]				8							8	8	100
Mother X1		1,7	0,21	12	8							8	8	100
(60) Roche		1,7	0,21	12	7	0	CVPG	1,7	0,087	33%	1,13	2,27	7	
Other					1	0							1	
							1x 24							
Mother Y1		1,2	0,13	11	8							8	8	100
(60) Roche		1,2	0,13	11	7	0	CVPG	1,25	0,057	33%	0,837	1,67	7	
Other					1	0							1	
							1x 24							
(241) PAPP-A (MoM)	[MoM]				11							11	10	91
Mother X1		0,122	0,024	20	11							11	10	91
(60) Roche		0,125	0,022	18	9	0	CVPG	0,134	0,01	33%	0,089	0,179	9	
Other					2	0							2	
							2x 24							
Mother Y1		0,671	0,042	6,3	11							11	11	100
(60) Roche		0,675	0,037	5,5	9	0	CVPG	0,696	0,036	33%	0,466	0,926	9	

EQA round: VV2/24 - Maternal Diagnostic Screening (Triple Test)

Deadline: 1.11.2024

Setup: groups - R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
Other					2	0	2x 24					2		
2. trimester														
(380) AFP (MoM)	[MoM]				12							10	9	90
Mother X2		0,921	0,091	9,9	12							10	9	90
(60) Roche		0,965	0,096	10	6	0	CVPG	0,957	0,071	23%	0,736	1,18	6	
Other					6	0						4		
							1x 1, 4x 12, 1x 179							
Mother Y2		0,513	0,066	13	12							10	9	90
(60) Roche		0,525	0,067	13	6	0	CVPG	0,528	0,03	23%	0,406	0,65	6	
Other					6	0						4		
							1x 1, 4x 12, 1x 179							
(382) hCG (MoM)	[MoM]				12							9	9	100
Mother X2		0,996	0,11	11	12							9	9	100
(60) Roche		0,965	0,096	10	6	0	CVPG	1,01	0,074	40%	0,606	1,42	6	
Other					6	0						3		
							1x 1, 3x 12, 1x 36, 1x 179							
Mother Y2		2,31	0,19	8,3	12							9	9	100
(60) Roche		2,27	0,1	4,6	6	0	CVPG	2,36	0,1	40%	1,41	3,31	6	
Other					6	0						3		
							1x 1, 3x 12, 1x 36, 1x 179							
(384) Estriol unconjug. (MoM)	[MoM]				12							12	9	75
Mother X2		0,913	0,23	25	12							12	11	92
(12) Beckman Coulter		1,01	0,16	15	5	0	CVPG	1,01	0,069	40%	0,606	1,42	5	
(29) Siemens (Immulite)		0,825	0,3	37	7	0	CVPG	0,82	0,16	40%	0,492	1,15	7	
Mother Y2		0,33	0,11	34	12							12	9	75
(12) Beckman Coulter		0,385	0,022	5,8	5	0	CVPG	0,438	0,038	40%	0,262	0,614	5	
(29) Siemens (Immulite)		0,285	0,13	44	7	0	CVPG	0,252	0,076	40%	0,151	0,353	7	